Oncology Innovations: LAG3 Inhibition in Melanoma Treatment is organized by Healio.
Release Date: September 15, 2023
Expiration Date: September 14, 2024
Overview
Provider Statement
Jointly provided by Partners for Advancing Clinical Education (PACE) and DKBmed, LLC.
Learning Objective
Upon completion of this activity, participants should be able to:
• Assess the efficacy and safety of anti-LAG-3/PD-1 combination regimens (approved and under investigation) for patients with metastatic melanoma
• Discuss the role of dual LAG-3/PD-1 checkpoint blockade regimens in treatment plans for patients with metastatic melanoma